5/27/2023 0 Comments Idarucizumab dose![]() Dabigatran etexilate (DE), 220 mg bid in healthy subjects and 150 mg bid in subjects with mild or moderate renal impairment (CL CR60 to <90 or 30 to <60, respectively) was given over 4 days to achieve the steady state conditions. Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of idarucizumab were investigated in a randomized, double-blind, placebo controlled two-way cross-over study in 46 male and female volunteers. It was further tested if a second administration of idarucizumab 2 months later was safe and well tolerated. In addition, it was tested whether oral intake of dabigatran etexilate 24 hrs after idarucizumab treatment could restore dabigatran related anticoagulation. In the present study it was determined whether and to what extent doses of up to 5 g idarucizumab would reverse the anticoagulant effects of dabigatran in male and female healthy mid-aged, elderly and renally impaired volunteers. Previously the dabigatran antidote (idarucizumab) has demonstrated immediate, complete and sustained reversal of dabigatran induced anti-coagulation in healthy male volunteers. Bleeding management can be achieved through established therapies however specific antidotes are not yet available for these agents to further facilitate patient management in cases needed. Recently, the advent of the direct oral anticoagulants (DOAC) has changed medical practice significantly nevertheless all anticoagulants are associated with an increased risk of bleeding. So far, Vitamin K antagonists have been the main drug of choice. Oral anticoagulation is an effective therapy to prevent and treat thromboembolic events. ![]()
0 Comments
Leave a Reply. |